High-dose omeprazole: Use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping

Therapeutic Drug Monitoring

Volumn 21, Issue 5, 1999, Pages 526-531

  Kovacs, Peter ^a   Edwards, David J ^b   Lalka, David ^c   Scheiwe, Werner M ^d   Stoeckel, Klaus ^e  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b WAYNE STATE UNIVERSITY   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d Mepha Ltd   (Switzerland)

^e Clinpharm Support   (Switzerland)

Author keywords

Bioequivalence; CYP2C19; Genotype; Omeprazole; Phenotype

Indexed keywords

5 HYDROXYOMEPRAZOLE; OMEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG FORMULATION; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHARMACOGENETICS; PHENOTYPE; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 0032880175     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199910000-00006     Document Type: Article

References (26)

1. Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993;36:521-530.
2. Chiba K, Kobayashi K, Manabe K, et al. Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 1993;266: 52-59.
3. Sohn D-R, Koyayashi K, Chiba K, et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992;262:1195-1202.
4. Andersson T, Regardh C-G, Dahl-Puustinen M-L, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990;12:415-416.
5. Caraco Y, Lagerstrom P-O, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996;60:157-167.
6. Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995;58:143-154.
7. Andersson T, Andren K, Cederberg C, et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990;29:557-563.
8. Ching MS, Mihaly GW, Angus PW, et al. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. Br J Clin Pharmacol 1991;31:166-170.
9. Howden CW, Meredith PA, Forrest JAH, Reid JL. Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol 1984;26:641-643.
10. Rost KL, Roots I. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 1996;23:1491-1497.
11. Chang M, Tybring G, Dahl M-L, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-518.
12. Andersson T, Bergstrand R, Cederberg C. Influence of acid secretory status on absorption of omeprazole from enteric coated granules. Br J Clin Pharmacol 1991;31:275-278.
13. Wedlund PJ, Wilkinson GR. In vivo and in vitro measurement of CYP2C19 activity. Methods Enzymol 1996;272:132-139.
14. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. clin Pharmacol Ther 1995;57:662-669.
15. Chang M, Dahl M-L, Tybring G, et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358-363.
16. Roh H-K, Dahl M-L, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6:547-551.
17. Marinac JS, Balian JD, Foxworth JW, et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype. Clin Pharmacol Ther 1996;60:138-144.
18. Rost KL, Brockmoller J, Esdorn F, Roots I. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatology 1995;23:268-277.
19. Amantea M, Narang PK. Improved procedure for quantitation of omeprazole and metabolites using reversed-phase high-performance liquid chromatography. J Chrom 1988;426:216-222.
20. Stubbins MJ, Harries LW, Smith G, et al. Genetic analysis of the human cytochrome P4502C9 locus. Pharmacogenetics 1996;6: 429-139.
21. Goldstein JA, Blaisdell J. Genetic tests which identify the principle defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 1996;272:210217.
22. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian population. Clin Pharmacol Ther 1985;38:402-408.
23. Bertilsson L, Lou YQ, Du YL. et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylation of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-397.
24. De Morals SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;22:15419-15422.
25. De Morais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46: 594-598.
26. Brosen K, deMorais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995;5: 312-317.